Renin Angiotensin System - CoronaVirus (SRA-COV)

Public Assistance-Hospitals of Marseille (AP-HM)

Status

Unknown

Conditions

COVID 19

Treatments

Other: blood draw

Study type

Interventional

Funder types

Other

Identifiers

NCT04337008

2020-A00795-34 (Other Identifier)

2020-16

Details and patient eligibility

About

The aim of the study is to demonstrate overactivation of Renin Angiotensine System (RAS) in positives COVID-19 patient, especially in those with the most serious clinical forms where the mortality of patients in intensive care is on average 50%.

We are expecting two groups: a group of 25 positive COVID 19 patients in intensive care and a group of 25 positive COVID 19 hospitalized patients in conventional hospitalisation. We will measure RAS, serum potassium and collect data on the treatment of these patients (especially antihypertensive therapy) one week apart (at the patient'entry into hospital and 7 days later).

This is a preliminary study that could possibly allow the start of a therapeutic trial in order to test the effectiveness of RAS blocker treatments in this condition.

Enrollment

50 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Positive COVID 19 patients hospitalized in conventionnal hospitalisation
Patients hospitalized in intensive care secondary to COVID-19 : Patient under invasive mechanical ventilation (PaO2 / FiO2 ratio <300; PEEP> = 5 cmH20; PCR SARS-CoV-2 positive in a pharyngeal or respiratory sample; PaO2 / FiO2 ratio> 300)

Exclusion criteria

Minor patient
Patient deprived of liberty
Patient's refusal to participate in the study
Patient for whom therapeutic limitation measures such as non-admission to intensive care have been issued